Exenatide vs Amycretin
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Byetta, Bydureon
Exenatide is the original GLP-1 receptor agonist and it came from an unlikely source: the saliva of the Gila monster, a venomous desert lizard. It is a synthetic 39-amino-acid peptide (a copy of the natural exendin-4) sharing about 50% of its sequence with human GLP-1. It was developed by Amylin and Lilly (later owned by AstraZeneca) and sold as the twice-daily Byetta (FDA-approved 2005) and the once-weekly Bydureon (2012). AstraZeneca discontinued both brands in the US in October 2024 for business reasons, not safety, and a generic twice-daily exenatide from Amneal (approved November 2024) launched in April 2025. It was the first drug to successfully turn the short-lived incretin hormone into a real diabetes therapy.
Also: Zenagamtide, NNC0487-0111
Amycretin is Novo Nordisk's single-molecule agonist of both the GLP-1 and amylin receptors, developed as a once-weekly injection and a once-daily pill. Early trials produced some of the biggest weight-loss numbers seen with any obesity drug so far, and the injectable version entered phase 3 (the AMAZE program) in 2026. It is not approved anywhere, and everything known about it comes from company-run trials of up to 36 weeks.
Key Comparison Insights
- Exenatide is FDA approved, while Amycretin remains in research stages.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Exenatide has stronger research evidence (FDA Approved) compared to Amycretin (Human Trials).
Detailed Comparison
| Attribute | Exenatide | Amycretin |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Exenatide binds and activates the GLP-1 receptor, triggering glucose-dependent insulin secretion, suppressing excess glucagon, slowing gastric emptying, and increasing satiety. The reason a lizard peptide beat human GLP-1 to market is durability: native GLP-1 is chewed up by the DPP-4 enzyme within about two minutes, while exendin-4 resists that enzyme and circulates with a half-life of roughly 2.4 hours. Endocrinologist John Eng isolated the peptide in the early 1990s after noting the Gila monster could go long stretches without eating while keeping blood sugar stable. The once-weekly Bydureon formulation traps the peptide in slowly dissolving polymer microspheres so a single injection releases drug over days. | Amycretin hits two appetite systems at once. The GLP-1 side slows stomach emptying, boosts insulin release after meals, and dampens appetite in the brain, the same biology behind semaglutide. The amylin side mimics a hormone your pancreas releases alongside insulin, which acts on the brainstem to make you feel full sooner and also curbs glucagon after eating. Novo combined these two signals in one molecule rather than mixing two drugs (which is what its CagriSema combination does). The bet is that the two pathways add together, giving more weight loss than either alone. That idea fits the early data, but it has not yet been tested head-to-head against semaglutide or tirzepatide in a large trial. |
| Common Dosing | 5-10 mcg twice daily Twice daily, within 60 minutes before morning and evening meals | Trial doses of 1.25-40 mg once weekly (injection) Once weekly (injection) or once daily (tablet) |
| Administration | Subcutaneous injection | Subcutaneous injection once weekly, or oral tablet once daily (separate formulations) |
| Typical Duration | Long-term / chronic use | 20-36 weeks in published trials; phase 3 runs longer |
| Best Time to Take | Within 60 minutes before the morning and evening meals | Same day each week (injection); trial protocols set timing for the tablet |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Exenatide is a long-approved drug with a deep human trial record, not an experimental compound. Its development is well documented in the peer-reviewed literature, including a 2012 review in Regulatory Peptides tracing it from Gila monster venom to an approved antidiabetic. In type 2 diabetes trials it lowered HbA1c and produced modest weight loss, with nausea being the most common side effect, usually fading over time. The EXSCEL cardiovascular outcomes trial found once-weekly exenatide was safe for the heart but did not show a statistically significant reduction in cardiovascular events, which is part of why newer agents like semaglutide and dulaglutide have largely overtaken it. There are rare post-marketing reports of acute pancreatitis, and it is not recommended in severe kidney impairment. Overall, strong human evidence, but now considered an older option in the class. | Two early trials were published in The Lancet in June 2025. In the subcutaneous phase 1b/2a trial (125 adults with overweight or obesity), the estimated weight loss assuming full adherence was 24.3% at 60 mg over 36 weeks and 22.0% at 20 mg over 36 weeks, versus roughly flat weight on placebo, with no plateau by the end of treatment. A separate phase 1 trial of the oral tablet (144 people, 12 weeks) showed up to 13.1% loss at the highest dose. In November 2025 Novo reported a 36-week phase 2 trial in 448 adults with type 2 diabetes: up to 14.5% weight loss with weekly injections (2.6% on placebo), up to 10.1% with the daily pill, and HbA1c drops of up to 1.8 points. Side effects were mostly gastrointestinal, dose-related, and mild to moderate. Novo moved both forms into phase 3; AMAZE 1 (weekly injection at 1.25, 5, 20 or 40 mg versus placebo, about 1,150 people without diabetes) is registered as NCT07339423 with completion expected in 2029. Honest caveats: the headline numbers come from small trials using an efficacy estimand that assumes everyone stayed on drug, and long-term safety is unknown. |
Frequently Asked Questions: Exenatide vs Amycretin
What is the difference between Exenatide and Amycretin?
Exenatide is a weight loss peptide that exenatide is the original glp-1 receptor agonist and it came from an unlikely source: the saliva of the gila monster, a venomous desert lizard. it is a synthetic 39-amino-acid peptide (a copy of the natural exendin-4) sharing about 50% of its sequence with human glp-1. it was developed by amylin and lilly (later owned by astrazeneca) and sold as the twice-daily byetta (fda-approved 2005) and the once-weekly bydureon (2012). astrazeneca discontinued both brands in the us in october 2024 for business reasons, not safety, and a generic twice-daily exenatide from amneal (approved november 2024) launched in april 2025. it was the first drug to successfully turn the short-lived incretin hormone into a real diabetes therapy. Amycretin is a weight loss peptide that amycretin is novo nordisk's single-molecule agonist of both the glp-1 and amylin receptors, developed as a once-weekly injection and a once-daily pill. early trials produced some of the biggest weight-loss numbers seen with any obesity drug so far, and the injectable version entered phase 3 (the amaze program) in 2026. it is not approved anywhere, and everything known about it comes from company-run trials of up to 36 weeks. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Exenatide or Amycretin?
Neither is universally "better" - the choice depends on your specific goals. Exenatide is typically used for weight loss purposes, while Amycretin is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Exenatide and Amycretin be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Exenatide and Amycretin together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.